FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
暂无分享,去创建一个
Richard Pazdur | Robert Justice | R. Pazdur | R. Justice | Martin H. Cohen | B. Mann | John R. Johnson | John R Johnson | Bhupinder S Mann | Martin H Cohen | M. Cohen
[1] M. Duvic,et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.
[2] E. Knobler. Current management strategies for cutaneous T-cell lymphoma. , 2004, Clinics in dermatology.
[3] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[4] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[5] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[6] M. Duvic,et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Zelenetz,et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Ramalingam,et al. Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies , 2007, Clinical Cancer Research.
[10] G. Wood,et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.
[11] S. Bates,et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.
[12] Scott E. Smith,et al. Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228 , 2005 .
[13] P. Marks,et al. Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.
[14] A. Oseroff,et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Kuzel,et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[17] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.